Single-Arm, Open Label, Interventional Phase II Clinical Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy
Phase of Trial: Phase II
Latest Information Update: 17 Jan 2020
Price : $35 *
At a glance
- Drugs Busulfan (Primary) ; Cyclophosphamide (Primary) ; Fludarabine (Primary) ; Granulocyte colony-stimulating factors (Primary) ; Melphalan (Primary) ; Mycophenolate mofetil (Primary) ; Mycophenolate mofetil (Primary) ; Spanlecortemlocel (Primary) ; Tacrolimus (Primary)
- Indications Haematological malignancies
- Focus Therapeutic Use
- 02 Jan 2019 Planned primary completion date changed from 1 Jun 2023 to 1 Jul 2023.
- 02 Jan 2019 Planned End Date changed from 1 Jun 2023 to 1 Aug 2023.
- 02 Jan 2019 Status changed from not yet recruiting to recruiting.